A Systematic Review of Cell Therapy Modalities and Outcomes in Cerebral Palsy

Overview

Journal Mol Cell Biochem

Publisher Springer

Specialty Biochemistry

Date 2024 Jul 20

PMID 39033213

Authors

Ayberk Akat

Erdal Karaoz

Affiliations

Soon will be listed here.

Abstract

Cerebral palsy is widely recognized as a condition that results in significant physical and cognitive disabilities. Interventions aim to improve the quality of life and reduce disability. Despite numerous treatments and significant advancements, cerebral palsy remains incurable due to its diverse origins. This review evaluated clinical trials, studies, and case reports on various cell therapy approaches for cerebral palsy. It assessed the clinical outcomes of applying different cell types, including mesenchymal stem cells, olfactory ensheathing cells, neural stem/progenitor cells, macrophages, and mononuclear cells derived from peripheral blood, cord blood, and bone marrow. In 60 studies involving 1474 CP patients, six major adverse events (0.41%) and 485 mild adverse events (32.9%) were reported. Favorable therapeutic effects were observed in 54 out of 60 cell therapy trials, indicating a promising potential for cell treatments in cerebral palsy. Intrathecal MSC and BM-MNC applications revealed therapeutic benefits, with MSC studies being generally safer than other cell therapies. However, MSC and BM-MNC trials have shown inconsistent results, with some demonstrating superior efficacy for certain outcomes. Cell dosage, transplantation route, and frequency of administration can affect the efficacy of these therapies. Our findings highlight the promise of cell therapies for improving cerebral palsy treatment and stress the need for ongoing research to refine treatment protocols and enhance safety. To establish conclusive evidence on the comparative effectiveness of various cell types in treating cerebral palsy, randomized, double-blind clinical trials are essential.

References

Kirby R, Wingate M, Braun K, Doernberg N, Arneson C, Benedict R . Prevalence and functioning of children with cerebral palsy in four areas of the United States in 2006: a report from the Autism and Developmental Disabilities Monitoring Network. Res Dev Disabil. 2011; 32(2):462-9. DOI: 10.1016/j.ridd.2010.12.042. View

Christensen D, Braun K, Doernberg N, Maenner M, Arneson C, Durkin M . Prevalence of cerebral palsy, co-occurring autism spectrum disorders, and motor functioning - Autism and Developmental Disabilities Monitoring Network, USA, 2008. Dev Med Child Neurol. 2013; 56(1):59-65. PMC: 4351771. DOI: 10.1111/dmcn.12268. View

Reid S, Meehan E, McIntyre S, Goldsmith S, Badawi N, Reddihough D . Temporal trends in cerebral palsy by impairment severity and birth gestation. Dev Med Child Neurol. 2016; 58 Suppl 2:25-35. DOI: 10.1111/dmcn.13001. View

Zhang J, Oskoui M, Shevell M . A population-based study of communication impairment in cerebral palsy. J Child Neurol. 2014; 30(3):277-84. DOI: 10.1177/0883073814538497. View

Mei C, Reilly S, Reddihough D, Mensah F, Pennington L, Morgan A . Language outcomes of children with cerebral palsy aged 5 years and 6 years: a population-based study. Dev Med Child Neurol. 2015; 58(6):605-11. DOI: 10.1111/dmcn.12957. View

Pakula A, Braun K, Yeargin-Allsopp M . Cerebral palsy: classification and epidemiology. Phys Med Rehabil Clin N Am. 2009; 20(3):425-52. DOI: 10.1016/j.pmr.2009.06.001. View

Nelson K . Causative factors in cerebral palsy. Clin Obstet Gynecol. 2008; 51(4):749-62. DOI: 10.1097/GRF.0b013e318187087c. View

MacLennan A, Thompson S, Gecz J . Cerebral palsy: causes, pathways, and the role of genetic variants. Am J Obstet Gynecol. 2015; 213(6):779-88. DOI: 10.1016/j.ajog.2015.05.034. View

McMichael G, Bainbridge M, Haan E, Corbett M, Gardner A, Thompson S . Whole-exome sequencing points to considerable genetic heterogeneity of cerebral palsy. Mol Psychiatry. 2015; 20(2):176-82. DOI: 10.1038/mp.2014.189. View

10.

van Eyk C, Corbett M, MacLennan A . The emerging genetic landscape of cerebral palsy. Handb Clin Neurol. 2018; 147:331-342. DOI: 10.1016/B978-0-444-63233-3.00022-1. View

11.

Nahm N, Graham H, Gormley Jr M, Georgiadis A . Management of hypertonia in cerebral palsy. Curr Opin Pediatr. 2017; 30(1):57-64. DOI: 10.1097/MOP.0000000000000567. View

12.

Park T, Dobbs M, Cho J . Evidence Supporting Selective Dorsal Rhizotomy for Treatment of Spastic Cerebral Palsy. Cureus. 2018; 10(10):e3466. PMC: 6300384. DOI: 10.7759/cureus.3466. View

13.

Novak I, Morgan C, Adde L, Blackman J, Boyd R, Brunstrom-Hernandez J . Early, Accurate Diagnosis and Early Intervention in Cerebral Palsy: Advances in Diagnosis and Treatment. JAMA Pediatr. 2017; 171(9):897-907. PMC: 9641643. DOI: 10.1001/jamapediatrics.2017.1689. View

14.

Novak I, Morgan C, Fahey M, Finch-Edmondson M, Galea C, Hines A . State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy. Curr Neurol Neurosci Rep. 2020; 20(2):3. PMC: 7035308. DOI: 10.1007/s11910-020-1022-z. View

15.

Novak I, Paton M, Griffin A, Jackman M, Blatch-Williams R, Finch-Edmondson M . The potential of cell therapies for cerebral palsy: where are we today?. Expert Rev Neurother. 2023; 23(8):673-675. DOI: 10.1080/14737175.2023.2234642. View

16.

Sharma A, Gokulchandran N, Chopra G, Kulkarni P, Lohia M, Badhe P . Administration of autologous bone marrow-derived mononuclear cells in children with incurable neurological disorders and injury is safe and improves their quality of life. Cell Transplant. 2012; 21 Suppl 1:S79-90. DOI: 10.3727/096368912X633798. View

17.

Purandare C, Shitole D, Belle V, Kedari A, Bora N, Joshi M . Therapeutic potential of autologous stem cell transplantation for cerebral palsy. Case Rep Transplant. 2012; 2012:825289. PMC: 3505957. DOI: 10.1155/2012/825289. View

18.

Mancias-Guerra C, Marroquin-Escamilla A, Gonzalez-Llano O, Villarreal-Martinez L, Jaime-Perez J, Garcia-Rodriguez F . Safety and tolerability of intrathecal delivery of autologous bone marrow nucleated cells in children with cerebral palsy: an open-label phase I trial. Cytotherapy. 2014; 16(6):810-20. DOI: 10.1016/j.jcyt.2014.01.008. View

19.

Sharma A, Sane H, Kulkarni P, Dsa M, Gokulchandran N, Badhe P . Improved Quality of Life in A Case of Cerebral Palsy after Bone Marrow Mononuclear Cell Transplantation. Cell J. 2015; 17(2):389-94. PMC: 4503853. DOI: 10.22074/cellj.2016.3754. View

20.

Sharma A, Sane H, Gokulchandran N, Kulkarni P, Gandhi S, Sundaram J . A clinical study of autologous bone marrow mononuclear cells for cerebral palsy patients: a new frontier. Stem Cells Int. 2015; 2015:905874. PMC: 4348592. DOI: 10.1155/2015/905874. View